Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,778 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Wood RA, et al. Among authors: iqbal a. N Engl J Med. 2024 Mar 7;390(10):889-899. doi: 10.1056/NEJMoa2312382. Epub 2024 Feb 25. N Engl J Med. 2024. PMID: 38407394 Clinical Trial.
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy.
Chinthrajah RS, Jones SM, Kim EH, Sicherer SH, Shreffler W, Lanser BJ, Atri N, Babineau DC, Adelman DC, Iqbal A, Limb SL, Rudman Spergel AK, Togias A, Wood RA. Chinthrajah RS, et al. Among authors: iqbal a. J Allergy Clin Immunol. 2022 Jun;149(6):2166-2170.e1. doi: 10.1016/j.jaci.2021.12.789. Epub 2022 Jan 11. J Allergy Clin Immunol. 2022. PMID: 35026206 Free PMC article.
Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).
Wood RA, Chinthrajah RS, Rudman Spergel AK, Babineau DC, Sicherer SH, Kim EH, Shreffler WG, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Kulis M, Iqbal A, Kaufman D, Umetsu DT, Ligueros-Saylan M, Uddin A, Fogel RB, Lussier S, Mudd K, Poyser J, MacPhee M, Veri M, Davidson W, Hamrah S, Long A, Togias A; OUtMATCH study team. Wood RA, et al. Among authors: iqbal a. J Allergy Clin Immunol Glob. 2022 Jul 21;1(4):225-232. doi: 10.1016/j.jacig.2022.05.006. eCollection 2022 Nov. J Allergy Clin Immunol Glob. 2022. PMID: 37779534 Free PMC article.
Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.
Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, Kattan M, Kianifard F, Ortiz B, Haselkorn T, Iqbal A, Rosén K, Trzaskoma B, Busse WW. Chipps BE, et al. Among authors: iqbal a. J Allergy Clin Immunol. 2017 May;139(5):1431-1444. doi: 10.1016/j.jaci.2017.03.002. J Allergy Clin Immunol. 2017. PMID: 28477722 Free article. Review.
Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
Casale TB, Win PH, Bernstein JA, Rosén K, Holden M, Iqbal A, Trzaskoma BL, Yang M, Antonova EN, Murphy T, Scarupa MD, Sofen H, Kaplan A. Casale TB, et al. Among authors: iqbal a. J Am Acad Dermatol. 2018 Apr;78(4):793-795. doi: 10.1016/j.jaad.2017.10.010. Epub 2017 Oct 14. J Am Acad Dermatol. 2018. PMID: 29037993 Free article. Clinical Trial. No abstract available.
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria.
Maurer M, Kaplan A, Rosén K, Holden M, Iqbal A, Trzaskoma BL, Yang M, Casale TB. Maurer M, et al. Among authors: iqbal a. J Allergy Clin Immunol. 2018 Mar;141(3):1138-1139.e7. doi: 10.1016/j.jaci.2017.10.018. Epub 2017 Nov 10. J Allergy Clin Immunol. 2018. PMID: 29132956 Clinical Trial. No abstract available.
1,778 results